Frank Dellanna

5.0k total citations
41 papers, 656 citations indexed

About

Frank Dellanna is a scholar working on Hematology, Nephrology and Genetics. According to data from OpenAlex, Frank Dellanna has authored 41 papers receiving a total of 656 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 20 papers in Nephrology and 7 papers in Genetics. Recurrent topics in Frank Dellanna's work include Erythropoietin and Anemia Treatment (23 papers), Dialysis and Renal Disease Management (15 papers) and Iron Metabolism and Disorders (10 papers). Frank Dellanna is often cited by papers focused on Erythropoietin and Anemia Treatment (23 papers), Dialysis and Renal Disease Management (15 papers) and Iron Metabolism and Disorders (10 papers). Frank Dellanna collaborates with scholars based in Germany, United Kingdom and France. Frank Dellanna's co-authors include C. A. Baldamus, Andreas Thomas, Mario Thevis, Wilhelm Schänzer, Joachim Hertel, Zhu Li, William Strauss, Iain C. Macdougall, Werner Kleophas and Ulrike B. Hendgen‐Cotta and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Frank Dellanna

39 papers receiving 631 citations

Peers

Countries citing papers authored by Frank Dellanna

Since Specialization

Citations

This map shows the geographic impact of Frank Dellanna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Dellanna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Dellanna more than expected).

Fields of papers citing papers by Frank Dellanna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Dellanna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Dellanna. The network helps show where Frank Dellanna may publish in the future.

Co-authorship network of co-authors of Frank Dellanna

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Dellanna. A scholar is included among the top collaborators of Frank Dellanna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Dellanna. Frank Dellanna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Combined detection of inhibitors of the activin receptor signaling pathways (IASPs) by means of LC-HRMS/MS for human doping control 2025 ·Scientific Reports ·P. Sakellariou, Katja Walpurgis, Andreas Thomas, Alexandre Marchand, Geoffrey D. Miller, Frank Dellanna, Mario Thevis	0
2	Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials 2024 ·Advances in Therapy ·Takayuki Hamano, Yusuke Yamaguchi, (unknown), (unknown), (unknown), Frank Dellanna, Tadao Akizawa, Jonathan Barratt	2
3	Long‐Term Excretion of Roxadustat in Urine 2024 ·Drug Testing and Analysis ·Tim Sobolevsky, Matthew Fedoruk, Frank Dellanna, Hans Geyer, Brian Ahrens, Mario Thevis	2
4	Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan 2024 ·Advances in Therapy ·Takayuki Hamano, Yusuke Yamaguchi, (unknown), (unknown), (unknown), Frank Dellanna, Jonathan Barratt, Tadao Akizawa	2
5	Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies 2023 ·Advances in Therapy ·Jonathan Barratt, Frank Dellanna, José Pórtoles, Gabriel Choukroun, Luca De Nicola, James Young, Nada Dimković, Michael Reusch	13
6	Iron Parameters in Patients Treated With Roxadustat for Anemia Associated With Chronic Kidney Disease: Post Hoc Analysis of the Non-Dialysis-Dependent or Incident Dialysis Population From Four Phase 3 Studies 2022 ·SPIRE - Sciences Po Institutional REpository ·Ciro Esposito, Jonathan Barratt, Frank Dellanna, José Pórtoles, Gabriel Choukroun, Luca De Nicola, Michael Reusch, (unknown), (unknown), Nada Dimković	1
7	Epoetin alfa biosimilar (HX575): A review of 15 years’ post-approval clinical experience 2022 ·Critical Reviews in Oncology/Hematology ·Pere Gascón, David Goldsmith, Matti Aapro, Frank Dellanna, (unknown), (unknown)	2
8	Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study 2019 ·BMC Nephrology ·Christian Combe, Johannes F.E. Mann, David Goldsmith, Frank Dellanna, Philippe Zaoui, Gérard M. London, Kris Denhaerynck, Andriy Krendyukov, Ivo Abraham, Karen MacDonald	5
9	First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis 2019 ·PLoS ONE ·Lutz Renders, Klemens Budde, Christian Rosenberger, (unknown), Dorine W. Swinkels, Frank Dellanna, Werner Feuerer, Ming Wen, Christiane M. Erley, (unknown), Claudia Sommerer, Matthias Schaier, (unknown), Louis A. Matis	51
10	Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience? 2018 ·Clinical Drug Investigation ·David Goldsmith, Frank Dellanna, Martin Schiestl, Andriy Krendyukov, Christian Combe	23
11	HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience 2017 ·Drug Design Development and Therapy ·Frank Dellanna, David Goldsmith, Andriy Krendyukov, Andreas Seidl, (unknown), Christian Combe	3
12	Vasculoprotective Effects of Dietary Cocoa Flavanols in Patients on Hemodialysis 2015 ·Clinical Journal of the American Society of Nephrology ·Tienush Rassaf, Christos Rammos, Ulrike B. Hendgen‐Cotta, Christian Heiß, Werner Kleophas, Frank Dellanna, Jürgen Floege, Gerd R. Hetzel, Malte Kelm	47
13	Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study) 2015 ·International Urology and Nephrology ·Loreto Gesualdo, Christian Combe, Adrian Covic, Frank Dellanna, David Goldsmith, Gérard M. London, Johannes F.E. Mann, Philippe Zaoui, Matthew Turner, (unknown), Karen MacDonald, Ivo Abraham	3
14	Interdisziplinäre Interaktion bei vaskulärer Erkrankung des Auges, Diabetes und diabetischer Retinopathie 2014 ·Der Ophthalmologe ·Werner Kleophas, Frank Dellanna	0
15	Macrophage migration inhibitory factor is associated with vascular dysfunction in patients with end-stage renal disease 2013 ·International Journal of Cardiology ·Christos Rammos, Ulrike B. Hendgen‐Cotta, (unknown), (unknown), Gerd R. Hetzel, Werner Kleophas, Frank Dellanna, Malte Kelm, Tienush Rassaf	29
16	Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Results from the PIOren Study 2012 ·SHILAP Revista de lepidopterología ·Jan Galle, Werner Kleophas, Frank Dellanna, Volkmar H.R. Schmid, (unknown), Gerhard Dikta, (unknown), W Fuchs, Thomas Först, Andreas Pfützner	8
17	Efficacy and safety of lanthanum carbonate in German patients on dialysis 2012 ·Clinical Nephrology ·Frank Dellanna, Helmut Reichel, (unknown)	9
18	The PRIMAVERA study protocol design: Evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non-anemic patients with chronic kidney disease 2011 ·Contemporary Clinical Trials ·Danilo Fliser, Frank Dellanna, Michael Koch, Jochen Seufert, Oliver Witzke, I.A. Hauser	8
19	Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study 2008 ·Clinical Nephrology ·(unknown), Jordi Bover, Frank Dellanna, (unknown), (unknown), Sánchez González, Peter L. Gross, (unknown), (unknown), P. M. Jehle	11
20	Internal filtration--advantage in haemodialysis? 1996 ·Nephrology Dialysis Transplantation ·Frank Dellanna, (unknown), C. A. Baldamus	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact